Dr. Hayder M. Saeed, MD

Dr. Saeed practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Saeed's NPI, 1851619118, was assigned on May 12, 2010. Dr. Saeed graduated from University of Baghdad College of Medicine in 2006. Dr. Saeed holds Kentucky license 46299.

Dr. Saeed's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Saeed's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Saeed to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saeed practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Saeed's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Saeed is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Saeed's licenses on file in 2 states: Kentucky and Florida.

Dmand AI lists chronic leukemia, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Saeed treats.

CMS data shows 303 Medicare services from Dr. Saeed across 4 procedure codes in 2024, for 166 Medicare patients. Medicare paid $25,003 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 166 Medicare patients who saw Dr. Saeed in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saeed's median patient age at 70, with 38% women.

In 2024, Dr. Saeed wrote 166 Medicare Part D claims for 47 patients. 49% of them were for generic drugs. CMS names the drug for 67 of them, across 2 drugs with 11 or more claims each, at $1,002,285 in total drug cost. In 2023, CMS named 79 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Saeed for performance year 2024, reported as part of a group. Dr. Saeed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Saeed as offering telehealth.

Dmand AI links 32 papers to Dr. Saeed, published from 2012 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease and Lymphoma, Extranodal NK-T-Cell. Dr. Saeed has published most often in Clin Lymphoma Myeloma Leuk. Dr. Saeed's most frequent co-authors are Lubomir Sokol, MD, Celeste M. Bello, MD and Julio C. Chavez, MD.

Dmand AI links Dr. Saeed to 6 clinical trials, 4 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Hodgkin Disease, Lymphoma and Lymphoma, B-Cell, Marginal Zone. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 133 general payments to Dr. Saeed from 28 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 56% of the total. Acrotech Biopharma LLC paid the most, $38,313.

Dmand AI lists 4 awards for Dr. Saeed, most recently AACR/ASCO Clinical trial workshop in Vail,CO in 2016.

Dr. Saeed graduated from University of Baghdad College of Medicine in 2006. Dr. Saeed is a member of ASCO and ASH.

Dr. Saeed is in network with 10 carriers, including Excellus BlueCross BlueShield, United Healthcare and Humana. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.